Saturday, June 13, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 227 of 1,261
  1. US 11497803

    Modulation of replicative fitness by deoptimization of synonymous codons

    THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  2. US 11498970

    Human antibodies to the human glucagon receptor and methods of use thereof to lower blood glucose or ketone levels

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  3. US 11497736

    Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease

    PTC THERAPEUTICS, INC. · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  4. CN 115348859

    Ophthalmic formulations comprising n-[5-(aminosulfonyl)-4-methyl-1, 3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl) phenyl] acetamide hemihydrate

    BAYER HEALTHCARE AG · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  5. US 11497815

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  6. WO 2022234069

    NOUVEAUX DÉRIVÉS DE 2-AMINOOXAZOLE ET LEUR UTILISATION POUR LE TRAITEMENT DE MALADIES INFECTIEUSES

    AB SCIENCE [FR] · Granted Nov 10, 2022 · Expires Nov 5, 2042

    granted
  7. US 2022354866

    IMMEDIATE RELEASE MULTILAYER TABLET

    ALKERMES PHARMA IRELAND LTD [IE] · Granted Nov 10, 2022 · Expires Nov 5, 2042

    granted
  8. US 11492624

    RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1

    Arrowhead Pharmaceuticals, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  9. US 11492623

    Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  10. US 11492406

    Methods and compositions for treating and preventing disease associated with alpha-v beta-8 integrin

    The Regents of the University of California · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  11. US 11492368

    Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway

    The Board of Regents of the University of Texas System · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  12. US 11492345

    Compounds and their methods of use

    PRAXIS PRECISION MEDICINES, INC. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  13. US 11491237

    Cyclodextrin protein drug conjugates

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  14. US 11491184

    Liquids rich in noble gas and methods of their preparation and use

    The Board of Regents of the University of Texas System · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  15. US 11492643

    Methods and compositions for treatment of a genetic condition

    Sangamo Therapeutics, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  16. US 11491231

    Peptide-oligonucleotide chimeras (POCs) as programmable biomolecular constructs for the assembly of morphologically-tunable soft materials

    Northwestern University · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  17. US 11492650

    Production of seleno-biologics in genomically recoded organisms

    The Board of Regents of the University of Texas System · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  18. US 11492617

    Compositions and methods for modulation of protein aggregation

    Ionis Pharmaceuticals, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  19. US 11492392

    Polynucleotides encoding anti-C5 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  20. US 11492350

    Compounds and methods of use

    Tango Therapeutics, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  21. US 11492351

    MTA-cooperative PRMT5 inhibitors

    Mirati Therapeutics, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  22. US 11492349

    IRAK inhibitors and method for making and using

    Rigel Pharmaceuticals, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  23. US 11491222

    Method of treating lower back pain

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  24. US 11491212

    Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B

    Catalyst Biosciences, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.